Loading clinical trials...
Loading clinical trials...
Cognixion ALS BCI Longitudinal Study
The goal of this study is refine the usability of a BCI based communication platform. The study will take place in the greater Los Angeles area and will enroll up to 10 participants with late stage ALS. Each subject will receive a Cognixion Axon-R augmented reality brain computer interface and associated communication software. The study duration is 3 months for each participant. The key questions that will be addressed in this study are: 1. How quickly can participants learn and gain confidence with a pure BCI interface. 2. How effective are alternate input modalities including eye tracking for this use case. 3. Identify the extent to which generative AI based personalization impacts the communication quality. Key measures include: ITR - information transfer rate SUS - system usability scale
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Cognixion
Santa Barbara, California, United States
Start Date
January 20, 2025
Primary Completion Date
August 30, 2025
Completion Date
October 31, 2025
Last Updated
February 5, 2025
10
ESTIMATED participants
Cognixion ONE
DEVICE
Lead Sponsor
Cognixion
NCT07235111
NCT07295990
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions